

ESPS Peer-review Report
Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 7687

Title: CLINICAL IMPACT OF OCCULT HBV INFECTION IN IMMUNOSUPPRESSED PATIENTS

Reviewer code: 00070577

Science editor: Ling-Ling Wen

Date sent for review: 2013-11-29 14:08

Date reviewed: 2014-01-19 17:17

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The authors reviewed occult HBV infection in immunosuppressed patients. The theme is interesting. I have some concerns about this paper; 1. The authors showed flow of management in figure1. Do the authors make the figure or do the author refer some guideline or paper? In this figure the authors refer only Lamivudine. How about entecavir? The authors should write more detail. 2. Is specific genotype susceptibility to activation? 3. When HBV are activated, what marker increase first? HBV-DNA? The authors should make figure about typical activation showing HBV-DNA, ALT etc. 4. The authors should make figure for manage HIV infection.

ESPS Peer-review Report
Name of Journal: World Journal of Hepatology

ESPS Manuscript NO: 7687

Title: CLINICAL IMPACT OF OCCULT HBV INFECTION IN IMMUNOSUPPRESSED PATIENTS

Reviewer code: 02861277

Science editor: Ling-Ling Wen

Date sent for review: 2013-11-29 14:08

Date reviewed: 2014-02-11 22:05

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> [Y] Grade B: minor language polishing	<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] High priority for publication
<input checked="" type="checkbox"/> [Y] Grade C (Good)	<input type="checkbox"/> [] Grade C: a great deal of language polishing	<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D (Fair)		BPG Search:	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E (Poor)	<input type="checkbox"/> [] Grade D: rejected	<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] No records	

COMMENTS TO AUTHORS

Sagnelli and colleagues widely described the current knowledge concerning the effects of occult HBV infection in immunosuppressed/compromised patients. Nonetheless, on the base of the data reported in the present review, I believe that the authors could still add or discuss three recent publications relative to this interesting topic. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S. Liver Int. 2014 Feb 6. doi: 10.1111/liv.12482. Lack of hepatitis B virus reactivation after anti-tumor necrosis factor α agents therapy in antibody to hepatitis B core antigen positive/hepatitis B surface antigen negative subjects with chronic inflammatory arthropathies. Biondo M1, Germano V1, Pietrosanti M1, Canzoni M1, Marignani M2, Stroffolini T3, Salemi S1, D'Amelio R4. Eur J Intern Med. 2014 Feb 1. pii: S0953-6205(14)00014-4. doi: 10.1016/j.ejim.2013.11.014. Development of cost-effective real-time PCR test: to detect a wide range of HBV DNA concentrations in the western amazon region of Brazil. de Oliveira Dos Santos A, Souza LF, Borzacov LM, Villalobos-Salcedo JM, Vieira DS. Virol J. 2014 Jan 28;11(1):16. doi: 10.1186/1743-422X-11-16.